CoChat

Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

BACKGROUND: People with diabetes have a high risk of developing micro- and macrovascular complications associated with diminished life expectancy and elevated treatment costs. Patient education programs can improve diabetes control in the short term, but their cost-effectiveness is uncertain. Our study aimed to analyze the lifelong cost-effectiveness of a nurse-led telecoaching program compared to usual care in people with type 2 diabetes from the perspective of the Belgian healthcare system. METHODS: The UKPDS Outcomes Model was populated with patient-level data from an 18-month randomized clinical trial in the Belgian primary care sector involving 574 participants; trial data were extrapolated to 40 years; Quality Adjusted Life Years (QALYs), treatment costs and Incremental Cost-Effectiveness Ratio (ICER) were calculated for the entire cohort and the subgroup with poor glycemic control at baseline ("elevated HbA1c subgroup") and the associated uncertainty was explored. RESULTS: The cumulative mean QALY (95% CI) gain was 0.21 (0.13; 0.28) overall and 0.56 (0.43; 0.68) in elevated HbA1c subgroup; the respective incremental costs were €1,147 (188; 2,107) and €2,565 (654; 4,474) and the respective ICERs €5,569 (€677; €15,679) and €4,615 (1,207; 9,969) per QALY. In the scenario analysis, repeating the intervention for lifetime had the greatest impact on the cost-effectiveness and resulted in the mean ICERs of €13,034 in the entire cohort and €7,858 in the elevated HbA1c subgroup. CONCLUSION: Taking into account reimbursement thresholds applied in West-European countries, nurse-led telecoaching of people with type 2 diabetes may be considered highly cost-effective within the Belgian healthcare system. TRIAL REGISTRATION: NCT01612520.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0163997

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Cost-effectiveness plane based on 999 bootstraps of costs and QALYs. Bootstrapping results of the entire cohort and the elevated HbA1c subgroup, base-case analysis with 40 years’ time horizon.
Fig 1 Cost-effectiveness plane based on 999 bootstraps of costs and QALYs. Bootstrapping results of the entire cohort and the elevated HbA1c subgroup, base-case analysis with 40 years’ time horizon.CC BY · PubMed Central
Fig 2 Cost-effectiveness acceptability curves for the COACH Program based on the Monte Carlo simulation of data from the entire cohort and the subgroup with poorly controlled HbA1c at baseline. Baseline analysis with 40 years’ time horizon.
Fig 2 Cost-effectiveness acceptability curves for the COACH Program based on the Monte Carlo simulation of data from the entire cohort and the subgroup with poorly controlled HbA1c at baseline. Baseline analysis with 40 years’ time horizon.CC BY · PubMed Central
Fig 3 ICER of The COACH Program as a function of the applied time horizon. Results for the entire cohort and the elevated HbA1c subgroup.
Fig 3 ICER of The COACH Program as a function of the applied time horizon. Results for the entire cohort and the elevated HbA1c subgroup.CC BY · PubMed Central
Fig 4 One-Way Sensitivity Analysis showing the influence of changing different parameters on the long-term cost-effectiveness in the entire cohort.
Fig 4 One-Way Sensitivity Analysis showing the influence of changing different parameters on the long-term cost-effectiveness in the entire cohort.CC BY · PubMed Central
Fig 5 One-Way Sensitivity Analysis showing the influence of changing different parameters on the long-term cost-effectiveness in the subgroup with poorly controlled HbA1c at baseline.
Fig 5 One-Way Sensitivity Analysis showing the influence of changing different parameters on the long-term cost-effectiveness in the subgroup with poorly controlled HbA1c at baseline.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 55 references

Research works printed but not linked: 2

  1. Cleemput I, Neyt M, Van de Sande S, Thiry N: Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre(KCE); 2012. KCE Report 183C. D/2012/10.273/54
  2. Van Brabandt H, Camberlin C, Vrijens F, Parmentier Y, Ramaekers D, Bonneux L. Variaties in de ziekenhuispraktijk bij acuut myocardinfarct in België. Bruxelles: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2005. KCE Reports vol. 14A. Ref. D/2005/10.273/11.

Cited by

Metadata

Authors
Odnoletkova, I., Ramaekers, D., Nobels, F., Goderis, G., Aertgeerts, B., & Annemans, L.
Affiliations
  • KU Leuven (BE)
  • Onze Lieve Vrouwziekenhuis Hospital (BE)
  • Ghent University (BE)
Corresponding author
Odnoletkova, Irina
Venue
PLOS ONE
Published
2016-10-11
Volume
11
Issue
10
Pages
e0163997
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2530593221
Cited by
33
References
55
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 2
FWCI
7.12
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Telemedicine and Telehealth Implementation
Keywords
type 2 diabetes, diabetes education, cost-effectiveness, quality-adjusted life years, incremental cost-effectiveness ratio, glycemic control, HbA1c, primary care, Belgian health care system
MeSH terms
Adolescent, Adult, Aged, Blood Glucose, Cost-Benefit Analysis, Counseling, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Life Style, Male, Markov Chains, Middle Aged, Patient Education as Topic, Primary Health Care, Telephone, Program Evaluation, Quality-Adjusted Life Years, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.